‘High Dollar’ Conflicts Should Nullify FDA Advisory Panelists – Public Citizen
This article was originally published in The Tan Sheet
Executive Summary
FDA advisory committee members with large financial conflicts of interest should be recused from meetings in which these conflicts may come into play, Public Citizen recommends after conducting a study on voting patterns
You may also be interested in...
FDA Extends Conflict Disclosure Policy To All Advisory Panel Members
FDA's draft guidance on the procedure for disclosing conflicts of interest will extend the agency's disclosure policy to cover all advisory committee members
Draft Conflict Of Interest Policy Affects Status Of Many FDA Cmte. Members
A "significant fraction" of current FDA advisory committee members' eligibility to vote and participate in meetings would be affected by a revised conflict of interest policy, FDA said
FDA advisory committee conflict of interest
"Special government employees" granted conflict of interest waiver for product-specific advisory committee meetings must provide declaration prior to meeting disclosing nature, magnitude of the conflict, agency says in draft guidance released in January. Document provides guidelines on type, amount of information that must be disclosed to the public...